Skip to main content

Table 1 Inclusion and exclusion criteria

From: THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy

Inclusion criteria
General ECOG 0–1
Age over 18 years
Written informed consent
Adequate hematological function:
-Granulocyte count > 1500/microl
-Hemoglobin level > 10 g/dl
-Platelet count > 100,000/microl
-ALT/AST: 7–45 UI/L
Primary tumour characteristics Histological proven adenocarcinoma of the rectum cT2-3, N0-2 or cT4 for anal sphincter involvement N0-2a, M0
Tumour located between 0 and 15 cm above the anal verge
Exclusion criteria
General Contraindications for MR
Pregnancy or lactating female patients
Prior radiotherapy in pelvic region
Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
No other malignancies in the previous history (except skin and initial cervical cancer)
Important comorbidities: severe cardiac or coagulative disease, moderate or severe restrictive/obstructive lung deficit, severe cognitive impairment, moderate and severe renal and hepatic impairment
Neoadjuvant chemotherapy
Primary tumour characteristics Mesorectal fascia involvement for tumor
Extramesorectal nodes involvement
Extramural venous invasion (EMVI)
Rectal mucinous adenocarcinoma histology
  1. ECOG Eastern Cooperative Oncology Group; ALT Alanine aminotransferase; AST Aspartate aminotransferase; MR Magnetic Resonance